Patent ID: 9603854
Date: 2017-03-28
CPC Classifications: A61K,A61N,A61P,C07D

Claim:
1. A method of treating cancer in a subject in need thereof, wherein the cancer is selected from cancer of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, esophagus and liver, lymphoblastic leukaemias, follicular lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer, comprising administration of an effective amount of a compound of formula (I): wherein: X and Y represent a carbon atom or a nitrogen atom, wherein X and Y may not simultaneously represent two carbon atoms or two nitrogen atoms; the Het moiety of the group represents an optionally substituted, aromatic or non-aromatic ring composed of 5, 6 or 7 ring members, which ring may have, in addition to the nitrogen represented by X or by Y, from one to 3 heteroatoms selected independently from oxygen, sulphur and nitrogen, wherein the nitrogen atom may be substituted by a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group or a —C(O)—O-Alk group wherein Alk is a linear or branched (C 1 -C 6 )alkyl group; R or R R R R R it being understood that: “aryl” means a phenyl, naphthyl, biphenyl or indenyl group, “heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen, “cycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group containing, from 4 to 10 ring members, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined may be optionally substituted by from 1 to 3 groups selected from optionally substituted linear or branched (C 1 -C 6 )alkyl, (C 3 -C 6 )spiro, linear or branched (C 1 -C 6 )alkoxy, (C 1 -C 5 )alkyl-S—, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, —COOR′, NR′R″, linear or branched (C 1 -C 6 )polyhaloalkyl, trifluoromethoxy, (C 1 -C 6 )alkylsulphonyl or halogen, wherein R′ and R″ independently of one another represent a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, and wherein the Het moiety of the group defined hereinbefore may be optionally substituted by a group selected from linear or branched (C 1 -C 6 )alkyl, hydroxy, NR 1 ′R 1 ″ and halogen, wherein R 1 ′ and R 1 ″ independently of one another represent a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, or an enantiomer, a diastereoisomer, or an addition salt thereof with a pharmaceutically acceptable acid or base.